Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285
Dr. DeAngelo elaborates on the clinical development of BLU-285 moving forward
Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis
Dr. DeAngelo expands on the outcomes from the phase 1 study of BLU-285 in advanced systemic mastocytosis
Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML
Dr. Lane elaborates on the efficacy outcomes of SL-401 consolidation therapy in patients with acute myeloid leukemia (AML)
Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD
Dr. Soiffer discusses ways to enhance the activity of Il-2 in chronic graft versus host disease (GVHD)
Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients
Dr. Pui tells us how he sees CAR T-cell therapy being used in pediatric acute lymphocytic leukemia (ALL) patients
Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated
Dr. Pui describes how precision medicine is changing the way we treat pediatric acute lymphocytic leukemia (ALL) today
Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint
Dr. Pui offers opinion on whether the FDA should accept minimal residual disease as a surrogate endpoint for regulatory approval
Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients
Dr. Pui elaborates on the optimal way to use minimal residual disease in pediatric and adult acute lymphocytic leukemia (ALL) patients
Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)
Dr. San-Miguel discusses the role of daratumumab in the front-line setting in multiple myeloma (MM) patients
Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment
Dr. Cortes tells us about the clinical data presented at ASH 2017 regarding treatment of front-line chronic myelogenous leukemia (CML) with bosutinib
Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL
Dr. Kahl elaborates on the evidence for using rituximab maintenance as a front-line treatment option with bendamustine-rituxan in follicular lymphoma (FL) patients
James R. Downing, MD, explains the mission of St. Jude Children’s Research Hospital
Dr. Downing shares how the mission of St. St. Jude Children’s Research Hospital is benefiting the pediatric cancer patient community
Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients
Dr. Lane describes how often clinicians will see frail acute myeloid leukemia (AML) patients and how this patient population should be managed
Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients
Dr. Lane offers his opinion on agents or treatment approaches a clinician should seek when managing frail acute myeloid leukemia (AML) patients
Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations
Dr. Lane discusses strategies for frail acute myeloid leukemia (AML) patients who do not qualify for intensive therapy
Andrew Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN
Dr. Lane discusses the outcomes from the pivotal phase 2 study of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study
Dr. San-Miguel shares his thoughts on whether daratumumab should be adopted in the first-line setting outside of the U.S. as a result of the ALCYON study
Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study
Dr. San-Miguel elaborates on the efficacy and safety outcomes of the ALCYON clinical study
Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy
Dr. Lohr elaborates on the kind of information we can get from liquid biopsy and how this compares to the information we can gather from bone marrow biopsy
Jens G. Lohr, MD, PhD, on utilizing liquid biopsy and how it compares to bone marrow biopsy
Dr. Lohr explains why we should use liquid biopsy and how it compares to bone marrow biopsy
James Essell, MD, discusses the concerns for patients receiving allogeneic transplantations
Dr. Essell elaborates on the conners for patients receiving allogeneic transplantations today
James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy
Dr. Essell explains how allogeneic transplantation is incorporated into hematologic malignancy today
Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma
Dr. Kahl offers his opinion on the unmet needs in Hodgkin lymphoma
Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma
Dr. Kahl shares information on the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma presented at ASH 2017
Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL
Dr. Kahl elaborates on his study evaluating ADCT-402 in diffuse large B-cell lymphoma (DLBCL)
Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib
Dr. Cortes elaborates on how generic imatinib is being adopted in clinical studies as an alternative to branded imatinib
Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML
Dr. Cortes shares what was talked about at ASH 2017 regarding treatment discontinuation in acute myeloid leukemia (AML) patients
Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)
Dr. Rule shares his thoughts on the clinical development plan with Imbruvica (ibrutinib) in mantle cell lymphoma (MCL)
Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017
Dr. Rule tells us about the presentation of the ibrutinib data in relapsed/refractory mantle cell lymphoma (MCL) presented at ASH 2017
Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia
Dr. Copelan offers his opinion on the highlights presented at ASH 2017 in the treatment of acute myeloid leukemia (AML)
Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma
Dr. Copelan elaborates on how allogeneic transplantation is being optimized for lymphoma and myeloma patients and how it compares with CAR T-cell therapy
Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML
Dr. Copelan on whether azacitidine can be used for induction in acute myeloid leukemia (AML)
James R. Downing, MD, discusses the significant studies presented at ASH 2017
Dr. Downing considers the significant clinical studies performed by physicians at St. Jude Children’s Research Hospital and presented at ASH 2017
James R. Downing, MD, on the evolution of St. Jude Children’s Research Hospital
Dr. Downing shares how St. Jude Children’s Research Hospital has been evolving to better meet the needs of pediatric cancer patients
John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL
Dr. Burke, on whether rituximab is an effective maintenance strategy after 1st line bendamustine-rituximab in previously untreated follicular lymphoma patients
Keith Pratz, MD, on the proportion of AML patients who fall into the frail category
Dr. Pratz describes the proportion of acute myeloid leukemia (AML) patients who fall into the category of frail
Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients
Dr. Pratz tells us how he is incorporating Vyxeos (liposomal daunorubicin and cytarabine) into his practice for acute myeloid leukemia (AML) patients
Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients
Dr. Pratz offers his opinion on strategies for treating frail acute myeloid leukemia (AML) patients who do not quality for intensive therapy
Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients
Dr. Pratz evaluates some of the exciting clinical data with FLT3 tyrosine kinase inhibitors in acute myeloid leukemia (AML) patients presented at ASH 2017
Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients
Dr. Pratz shares the outcomes of the venetoclax with decitabine or azacitidine study in treatment-naive acute myeloid leukemia (AML) patients
Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML
Dr. Pratz considers whether we can combine ivosidenib or enasidenib with standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients
Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML
Dr. Pratz discusses the epidemiology and cytogenetic risk associated with acute myeloid leukemia (AML)
Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types
Dr. Hagemeister offers his opinion on the effectiveness of CAR T-cell therapies outside of large cell lymphomas and whether we can apply this technology to other patient types
Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment
Dr. Hagemeister explains how PD-1 inhibitors are being incorporated into follicular lymphoma (FL) treatment programs
Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies
Dr. Hagemeister on the safety of CAR T-cell therapies for lymphoma patients and recommendations for managing toxicities associated with these therapies
Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies
Dr. Hagemeister shares what physicians should know about the development of CAR T-cell therapies in lymphoid malignancies
Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions
Dr. Lane discusses how minimal residual disease is being integrated into treatment decision making in acute myeloid leukemia (AML) patients
John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies
Dr. Burke, shares his thoughts on the top findings at ASH 2017 regarding lymphoid malignancies
John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma
Dr. Burke, comments on the safety and efficacy of adding atezolizumab to obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma
Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MM
Dr. Yimer considers the safety of combination daratumumab, cyclophosphamide, bortezomib, and dexamethasone in previously untreated and relapsed multiple myeloma (MM) patients
Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients
Dr. Yimer on how the combination of obinutuzumab and bendamustine improves outcomes, quality of life and symptoms when given to untreated chronic lymphocytic leukemia (CLL) patients
Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma
Dr. Hutchings shares his thoughts on the role of PET in the treatment and management of Hodgkin’s lymphoma
Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changing
Dr. Hutchings discusses how the results of the ECHELON-1 Phase 3 study in untreated Stage 3 or 4 Hodgkin’s lymphoma might change current practices
Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017
Dr. Wang tells us what exciting clinical data for acute myeloid leukemia (AML) patients was presented at ASH 2017
Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients
Dr. Wang, discusses what type of agents or treatment approaches a clinician should seek when managing frail acute myeloid leukemia (AML) patients
Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment
Dr. Wang, tells us how she is incorporating Vyxeos (liposomal daunorubicin and cytarabine) into her acute myeloid leukemia (AML) treatment strategy
Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy
Dr. Wang, suggests strategies for clinicians with frail acute myeloid leukemia (AML) patients who do not quality for intensive therapy
Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML
Dr. Wang elaborates on how minimal residual disease is being integrated into treatment decision making in acute myeloid leukemia (AML) patients
Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses
Dr. Boxer considers whether fostamatinib is effective in the maintenance of ITP responses
Parameswaran Hari, MD, MRCP, MS, considers the remaining unmet medical needs in MM
Dr. Hari describes the remaining major unmet medical needs in the treatment of multiple myeloma (MM) and the proportion of his patients that fall into this unmet need category
Parameswaran Hari, MD, MRCP, MS, discusses the clinical relevance of minimal residual disease
Dr. Hari elaborates on the clinical relevance of minimal residual disease for patients today
Parameswaran Hari, MD, MRCP, MS, provides an update on how MM patients are staged at diagnosis
Dr. Hari tells us how multiple myeloma (MM) patients are staged at initial diagnosis
Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017
Dr. Hari shares his opinion on the most exciting and promising studies regarding cellular immunotherapy presented at ASH 2017
Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients
Dr. Hari offers his thoughts on how the field of immunotherapy is evolving for multiple myeloma (MM) patients
Parameswaran Hari, MD, MRCP, MS, on checkpoint inhibitors and MM treatment algorithms
Dr. Hari explains how checkpoint inhibitors are being integrated into multiple myeloma (MM) treatment algorithms today
David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies
Dr. Miklos considers the possibility that ibrutinib could be used in combination with CAR T-cell therapies when treating aggressive relapsed/refractory lymphomas
David Miklos, MD, PhD, explains how ibrutinib is being studied for the treatment of GVHD
Dr. Miklos shares how ibrutinib is being studied for the treatment of chronic graft versus host disease (GVHD) today
David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD
Dr. Miklos outlines the optimal way to use ibrutinib in the treatment of chronic graft versus host disease (GVHD)
David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study
Dr. Miklos tells us about the outcomes of the ZUMA-1 clinical study and the long-term efficacy of CAR T-cell therapy
Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients
Dr. Boxer elaborates on how treating chronic lymphocytic leukemia (CLL) patients with obinutuzumab and bendamustine affects quality of life and symptoms
Michael Boxer, MD, considers broader uses for fostamatinib
Dr. Boxer offers his opinion on broader uses for fostamatinib
Paul Richardson, MD, on the importance of real world evidence (RWE)
Dr. Richardson provides insight into the importance of real world evidence (RWE) and how clinical data compares with actual usage in multiple myeloma patients
Paul Richardson, MD, shares the efficacy outcomes of GSK-916 in relapsed/refractory MM patients
Dr. Richardson describes the efficacy outcomes of the BCMA immune conjugate (GSK-916) in relapsed/refractory multiple myeloma patients
Paul Richardson, MD, on adding CAR T-cell therapy to multiple myeloma treatment algorithms
Dr. Richardson elaborates on adding CAR T-cell therapy into treatment algorithms for multiple myeloma
Robert Soiffer, MD, on other applications that IL-2 might have outside of treating chronic GVHD
Dr. Soiffer on other applications that IL-2 might have outside of treating chronic graft versus host disease (GVHD)
Robert Soiffer, MD, on some of the innovative approaches to treating chronic GVHD
Dr. Soiffer on some of the innovative approaches to treating chronic graft versus host disease (GVHD)
Robert Soiffer, MD, discusses current treatments available for chronic GVHD
Dr. Soiffer discusses current treatments available for chronic graft versus host disease (GVHD)
Robert Soiffer, MD, explains GVHD and some of the complications that come along with it
Dr. Soiffer explains chronic graft versus host disease (GVHD) and some of the complications that come along with it
Jane N. Winter, MD, discusses how CAR T-Cell therapies will impact the treatment of lymphomas
Dr. Winter discusses how CAR T-Cell therapies will impact the treatment of aggressive lymphomas
Jane N. Winter, MD, shares the clinical evidence supporting brentuximab vedotin in older patients
Dr. Winter shares the clinical evidence supporting the use of brentuximab vedotin in older patients with untreated classical Hodgkin’s Lymphoma
Jane N. Winter, MD, on whether checkpoint inhibitors can be used effectively in Hodgkin’s Lymphoma
Dr. Winter on whether checkpoint inhibitors can be used effectively in classical Hodgkin’s Lymphoma
Jane N. Winter, MD, explains how PD-1 and PD-L1 expression changes the way DLBCL is treated
Dr. Winter explains how PD-1 and PD-L1 expression changes the way Diffuse Large B-Cell Lymphoma (DLBCL) is treated
Robert M. Rifkin, MD, on excluding transplantation from MM treatment algorithms
Dr. Rifkin on if we are getting closer to excluding transplantation from Multiple Myeloma treatment algorithms
Robert M. Rifkin, MD, discusses if COMPASS is close to its goal of achieving whole genome sequencing
Dr. Rifkin discusses if COMPASS, the multiple myeloma registry, is getting closer to its goal of achieving whole genome sequencing
Robert M. Rifkin, MD, on the Connect Multiple Myeloma patient registry improving characterization
Dr. Rifkin on if the Connect Multiple Myeloma patient registry can help improve the characterization of MM
Robert M. Rifkin, MD, on how the Connect Multiple Myeloma patient registry is helping patients
Dr. Rifkin on how the Connect Multiple Myeloma patient registry is helping patients
Andre Goy, MD, tells us about the long-term outcomes of the ZUMA-1 trial
Dr. Goy tells us about the long-term outcomes of the ZUMA-1 trial
Andre Goy, MD tells us about the BTK combination with lenalidomide in MCL
tells us about the BTK combination with lenalidomide in relapsed/refractory mantle cell lymphoma (MCL)
Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL
Dr. Goy discusses the best strategy for using ibrutinib in mantle cell lymphoma (MCL)
David S. Siegel, MD, shares his thoughts on the most exciting clinical trial presented at ASH 2017
Dr. Siegel shares his thoughts on the most exciting clinical trial presented at ASH 2017
David S. Siegel, MD, discusses proteasome inhibitors and Multiple Myeloma
Dr. Siegel discusses which proteasome inhibitor delivers the best efficacy in the front line treatment of Multiple Myeloma
David S. Siegel, MD, discusses how stem cell transplant figures into MM treatment algorithms
Dr. Siegel discusses how autologous stem cell transplant figures into Multiple Myeloma treatment algorithms
David S. Siegel, MD, on how molecular profiling is helping drive treatment strategies
Dr. Siegel on the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol and how molecular profiling is helping drive treatment strategies
C. Ola Landgren, MD, discusses remaining major unmet medical needs for MM
Dr. Landgren discusses remaining major unmet medical needs for mutliple myeloma and what proportion of patients fall into this unmet need category
C. Ola Landgren, MD, discusses risk factors for developing AML or MDS after treatment of MM
Dr. Landgren discusses risk factors for developing acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after treatment of Multiple Myeloma
C. Ola Landgren, MD, discusses continuous therapy vs fixed duration therapy in MM patients
C. Ola Landgren, MD, discusses if continuous therapy is a better strategy than fixed duration therapy in Multiple Myeloma patients
C. Ola Landgren, MD, on MRD as a legitimate surrogate endpoint in multiple myeloma clinical trials
Dr. Landgren on MRD as a legitimate surrogate endpoint in multiple myeloma clinical trials
John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma
John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma
John Gerecitano, MD, on what genetic predictors of response we have for follicular lymphoma
Dr. Gerecitano tells us what genetic predictors of response do we have for the treatment of follicular lymphoma
John Gerecitano, MD, discusses how PET staging affects outcomes and prognosis of follicular lymphoma
Dr. Gerecitano discusses how PET staging affects outcomes and prognosis of follicular lymphoma
John Gerecitano, MD, on predictors of response to tazemetostat in diffuse large B-cell lymphoma
Dr. Gerecitano on predictors of response to tazemetostat in diffuse large B-cell lymphoma
John Gerecitano, MD, talks about tazemetostat’s class and mechanism of action
Dr. Gerecitano tells us about tazemetostat’s class, mechanism of action, and what makes it unique
Miles Prince, MD, discusses I-O compounds and T-Cell Lymphoma treatment algorithms
Dr. Prince discusses how I-O compounds are being integrated into T-Cell Lymphoma treatment algorithms
Miles Prince, MD, on which emerging compounds for T-Cell Lymphomas look promising
Dr. Prince shares which emerging compounds in late stage development for T-Cell Lymphomas look promising at addressing unmet medical need
Miles Prince, MD, on the challenges to recruit and accrue patients to rare-cancer clinical studies
Dr. Prince discusses the challenges of trying to recruit and accrue patients to rare-cancer clinical studies
Miles Prince, MD, discusses the efficacy and safety of brentuximab vedotin to treat CTCL patients
Dr. Prince discusses the efficacy and safety of brentuximab vedotin when using it to treat Cutaneous T-Cell Lymphoma (CTCL) patients
Miles Prince, MD, on the role CD30 plays when selecting a treatment algorithm for CTCL patients
Dr. Prince on the role CD30 plays when selecting a treatment algorithm for newly diagnosed Cutaneous T-Cell Lymphoma (CTCL) patients
Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
Dr. Prince tells us the issues and concerns to consider when choosing a treatment plan for newly diagnosed Cutaneous T-Cell Lymphoma (CTCL) patients
Sattva Neelapu, MD, on novel agents and up-front approaches showing efficacy in lymphomas
Dr. Neelapu discusses novel agents and up-front approaches showing efficacy in aggressive B-Cell lymphomas
Sattva Neelapu, MD, shares his approach to optimizing CAR T-Cell therapies
Dr. Neelapu shares his approach to optimizing CAR T-Cell therapies
Sattva Neelapu, MD, discusses efficacy results of the ZUMA-1 trial
Dr. Neelapu discusses the long-term efficacy results of the ZUMA-1 trial in patients with refractory aggressive Non-Hodgkin Lymphoma
John P. Leonard, MD, on the role social media plays in medicine
Dr. Leonard on the role social media plays in medicine
John P. Leonard, MD, on CAR-T cell therapies being developed for the treatment of lymphomas
Dr. Leonard explains how CAR-T cell therapies are being developed for the treatment of lymphomas
John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms
Dr. Leonard on the role checkpoint inhibitors play in lymphoma treatment algorithms
John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas
Dr. Leonard discusses what novel agents for treating aggressive lymphomas have the promise of improving outcomes
Gary Gordon, MD, PhD, on MRD endpoint for outcomes in the MURANO study
Dr. Gordon on how Minimal Residual Disease endpoint figures into the outcomes in the phase 3 MURANO study
Gary Gordon, MD, PhD, discusses safety concerns in the phase 3 MURANO clinical trial
Dr. Gordon discusses safety concerns in either regimen of the phase 3 MURANO clinical trial in Chronic Lymphocytic Leukemia patients
Gary Gordon, MD, PhD, discusses efficacy results of the phase 3 MURANO clinical trial
Dr. Gordon discusses efficacy results of the phase 3 MURANO clinical trial in Chronic Lymphocytic Leukemia patients
Matthew Davids, MD, on how checkpoint inhibitors are being developed for hematologic malignancies
Dr. Davids on how checkpoint inhibitors are being developed for post-allogeneic transplant hematologic malignancies
Sagar Lonial MD, FACP, on expectations for response in the challenging patient type
Dr. Lonial on what a physician can hope for in terms of response in the challenging patient type
Sagar Lonial MD, FACP, on MM patients not responding to monotherapy and combination regimens
Dr. Lonial on characteristics of Multiple Myeloma patients that do not respond to current monotherapy and combination regimens
Sagar Lonial MD, FACP, discusses unmet need for multiple myeloma patients
Given the many novel therapy introductions over the past 5 years in Multiple Myeloma as monotherapy, Dr. Lonial discusses the remaining unmet needs if any and what proportion of patients fall into this category
Sagar Lonial MD, FACP, on predicting venetoclax sensitivity in MM using biologic active assays
Dr. Lonial on predicting venetoclax sensitivity in multiple myeloma using biologic active assays
Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin Lymphoma
Dr. Cheson discusses the role of nivolumab in Hodgkin Lymphoma
Bruce D. Cheson, MD, discusses care, toxicities, and outcomes treating CLL patients with venetoclax
Dr. Cheson tells us the patterns of care, toxicities, and outcomes when treating CLL patients with venetoclax
Bruce D. Cheson, MD on choosing a front-line therapeutic regimen for CLL patients
Dr. Cheson on determinants to look for when choosing a front-line therapeutic regimen for Chronic Lymphocytic Leukemia patients
Sattva Neelapu, MD shares his advice for sites that are new to treating with CAR T-Cell therapies
Dr. Neelapu shares his advice for sites that are new to treating with CAR T-Cell therapies
Sattva Neelapu, MD shares safety results of the ZUMA-1 trial in patients with NHL
Dr. Neelapu shares long-term safety results of the ZUMA-1 trial in patients with refractory aggressive Non-Hodgkin Lymphoma
Matthew Davids, MD discusses his study using ibrutinib plus FCR in younger CLL patients
Dr. David tell us about the outcomes of his study using ibrutinib plus FCR in younger CLL patients
Matthew Davids, MD discusses how he typically treats front line CLL outside of a clinical study
Dr. Davids discusses how he typically treats front line CLL outside of a clinical study
John P. Leonard, MD discusses improving outcomes in high risk follicular lymphoma patients
Dr. Leonard discusses adding bortezomib to ofatumumab and bendamustine for induction in previously untreated high risk follicular lymphoma improve outcomes
Sagar Lonial MD, FACP tells us about the immunomodulatory mechanism of action of daratumumab
Dr. Lonial tells us about the immunomodulatory mechanism of action of daratumumab
Sagar Lonial MD, FACP on whether relapsed multiple myeloma patients should be profiled molecularly
Dr. Lonial on whether relapsed multiple myeloma patients should be profiled molecularly
Bruce D. Cheson, MD discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL
Dr. Cheson discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL
John P. Leonard, MD discusses lenalidomide plus rituximab for the treatment of MCL
Dr. Leonard discusses the combination of lenalidomide plus rituximab for the initial treatment of MCL
